BioAge Labs (NASDAQ:BIOA) was given a new $23.00 price target on by analysts at Morgan Stanley.
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
Show more
Live Event:
Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team:
support@newsquantified.com